Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

hTERT-derived peptide vaccine - Invectys

Next Previous
Drug Profile

hTERT-derived peptide vaccine - Invectys

Alternative Names: Human telomerase reverse transcriptase peptide-based vaccine - Invectys; UCP2-UCP4 vaccine - Invectys; UCPVax

Latest Information Update: 24 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Invectys
  • Developer Institut Pasteur; Regional and University Hospital of Besancon
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Glioblastoma

Most Recent Events

  • 17 Oct 2025 Efficacy and adverse event data from a phase II Optim-UCPVax trial in Non-small cell lung cancer presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
  • 01 Oct 2025 University hospital center in France plans a phase II trial for Glioblastoma (Combination therapy, Adjuvant therapy) in France (Injection) (CTIS2024-514399-42-00)
  • 30 May 2025 Updated efficacy and adverse events data from a phase I/II trial in Glioblastoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top